(4-(Cyclopentylcarbamoyl)phenyl)boronic acid → 1-Methylethyl 4-[({4'-[(cyclopentylamino)carbonyl]-4-biphenylyl}oxy)methyl]-1-piperidinecarboxylate

참여 물질

반응 단계

The title compound (14 mg, 12%) was prepared from {4-[(cyclopentylamino)carbonyl]phenyl}boronic acid (47 mg, 0.2 mmol) and 1-methylethyl 4-{[(4-bromophenyl)oxy]methyl}-1-piperidinecarboxylate (prepared as in Example 9, Step 2, 71 mg, 0.2 mmol) in a manner similar to Example 21, Step 3 and worked up in a manner similar to Example 9, Step 3. 1H NMR (400 MHz, CDCl3): δ 7.78 (d, 2H, J=8.4 Hz), 7.59 (d, 2H, J=8.4 Hz), 7.53 (d, 2H, J=8.8 Hz), 6.96 (d, 2H, J=8.8 Hz), 6.04 (d, 1 H, J=7.4 Hz), 4.97-4.86 (m, 1H), 4.48-4.37 (m, 1H), 4.21 (bs, 2H), 3.85 (d, 2H, J=6.4 Hz), 2.83-2.73 (m, 2H), 2.17-2.06 (m, 2H), 2.05-1.95 (m, 1H), 1.90-1.80 (m, 2H), 1.78-1.62 (m, 4H), 1.55-1.45 (m, 2H), 1.35-1.26 (m, 2H), 1.24 (d, 6H, J=6.2 Hz); LRMS (ESI), m/z 465 (M+H).

출처 및 근거